SCHEMBL1745150

SCHEMBL1745150

COC(=O)CCc1ccc2oc(-c3cccc(OC)c3)cc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 9/20 0.64
MAOB P27338 3/20 0.64
MAOA P21397 2/20 0.64
VDR P11473 1/20 0.54
PPARD Q03181 1/20 0.54
HDAC3 O15379 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
PTGES O14684 1/20 0.47
ALOX5 P09917 1/20 0.47
CYP26A1 O43174 1/20 0.47
CYP26B1 Q9NR63 1/20 0.47
KDM4E B2RXH2 2/20 0.47
CYP3A4 P08684 2/20 0.47
MAPK1 P28482 2/20 0.47
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745020 0.90 FFAR1 (0.77) FFAR1MAOBMAOAVDRPPARD
SCHEMBL1744659 0.87 MAOA (0.62) FFAR1MAOBMAOAPTGESALOX5
SCHEMBL3003302 0.83 CYP2C8 (0.67) FFAR1MAOBMAOAALOX5CYP2C8
SCHEMBL18224256 0.83 VDR (0.50) FFAR1MAOBMAOAVDRPPARD
SCHEMBL30861753 0.82 MAOB (0.63) FFAR1MAOBMAOAHDAC3HDAC1
SCHEMBL29214219 0.82 MAOB (0.63) FFAR1MAOBMAOAHDAC3HDAC1
SCHEMBL3001663 0.81 CYP2C8 (0.55) FFAR1PTGESALOX5KDM4ECYP3A4
SCHEMBL29214217 0.80 MAOB (0.60) FFAR1MAOBMAOAHDAC3HDAC1
SCHEMBL3006301 0.79 CYP2C8 (0.58) FFAR1MAOAKDM4ECYP3A4MAPK1
SCHEMBL12646450 0.78 MAOB (0.62) FFAR1MAOBVDRPPARDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885MAOB 4303/4885MAOA 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.